VistaGen Therapeutics

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression, and other central nervous system disorders. Its portfolio includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that the company is currently preparing for phase III clinical trial for social anxiety disorder, PH10, a neuroactive nasal spray that the company is planning for phase 2b development as a stand-alone treatment for major depressive disorder (MDD), and AV-101, which the company is developing for the treatment of MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia, and epilepsy. The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

VistaGen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. Its product portfolio includes Fasedienol (PH94B) nasal spray for social anxiety disorder, Itruvone (PH10) nasal spray for depression disorders, AV-101 oral NMDR glycine site antagonist for depression and neurological disorders, PH15 acute treatment for improvement of cognition, PH80 acute management of vasomotor symptoms due to menopause, and PH284 acute management of Wasting syndrome (Cachexia). The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

CompoSecure

Viant Technology

Granite Ridge Resources Inc

Puma Biotechnology

SNDL Inc.

SoFi Technologies

If you're searching for stocks under $15, look no further. These seven offerings, all priced below $15, present a unique opportunity for individual investors to profit from future development.

7 Stocks Under $15 Predicted to Boom in the Next 2 Years

PowerFleet Inc

Finding possibilities in investing frequently depends on finding companies attached to rapid expansion and value generation. Examine these three prospects, each selling at less than $10 per share and expected to see significant returns by 2027.

Millionaire Makers: 3 Stocks Under $10 Set to Skyrocket by 2027

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it will present posters detailing clinical trial data for fasedienol, an investigational pherine candidate in Phase 3 development for the acute treatment of social anxiety disorder (SAD), and PH80, a Phase 2 investigational pherine.

Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #clinicaltrial--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it has enrolled the first patient in its PALISADE-3 Phase 3 trial of fasedienol, an investigational pherine candidate in development for the acute treatment of social anxiety disorder (SAD). “Initiating PALISADE-3 is another major.

Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2

Albertsons Companies

ScanSource

Finding undiscovered opportunities can result in significant profits in an investment landscape frequently controlled by well-known giants. These three obscure stocks have the potential to provide impressive profits.

Secret Superstars: 3 Unknown Stocks to Turn $5K into $100K by 2027

Vistagen Therapeutics has proprietary platform technologies for developing innovative drugs for mental health disorders. The company's pipeline includes candidates for social anxiety disorder, major depressive disorder, vasomotor symptoms, and more. Vistagen's financial position is strong, with ample liquidity to support operations and fund clinical development programs.

Vistagen Therapeutics: Initial Analysis Of Fasedienol Points To Bullish

VistaGen Therapeutics is developing CNS drugs for anxiety, depression, and other disorders, with Fasedienol in phase 3 clinical trials. Fasedienol has advantages as a non-systemic, low-abuse anxiolytic and is seeking Breakthrough Therapy Designation. VTGN's diverse product pipeline includes treatments for social anxiety disorders, major depressive disorder, menopause symptoms, and more.

Why VistaGen Therapeutics Is A Buy: Fasedienol Potential For Anxiety Treatments

Pfizer

Progyny

Biote Corp

Dare Bioscience

Menopause is among the female health conditions with the highest unmet need and has 'enormous potential for innovative treatments,' according to McKinsey.

This overlooked corner of women's health could be a $350 billion market opportunity

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management will present and host one-on-one meetings during the Stifel 2024 Virtual CNS Days taking place March 19 to 20, 2024. Stifel 2024 Virtual CNS Days Shawn Singh, Chief Executive Officer, will participate in a fireside chat on Wednesday.

Vistagen to Present at Stifel 2024 Virtual CNS Days

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management will present and host one-on-one meetings at the TD Cowen 44th Annual Health Care Conference in Boston, Massachusetts, March 4 to 6, 2024. TD Cowen 44th Annual Health Care Conference Shawn Singh, Chief Executive Officer, will presen.

Vistagen to Present at TD Cowen 44th Annual Health Care Conference

The mean of analysts' price targets for VistaGen Therapeutics, Inc. (VTGN) points to a 160% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does VistaGen Therapeutics, Inc. (VTGN) Have the Potential to Rally 160% as Wall Street Analysts Expect?

Ardelyx

Vertex Pharmaceuticals

Investing in high-potential biotech stocks should catapult your portfolio to new heights. Picture this: a global biotech market valued at a whopping $1.55 trillion in 2023 is set to catapult to $3.08 trillion by 2030, with a compound annual growth rate of 14%.

3 Revolutionary Biotech Stocks Poised for 10X Surge

Immuneering Corp

Vir Biotechnology

The global biotechnology market is a treasure trove of hidden-gem biotech stocks. Valued at $1.55 trillion in 2023, it is anticipated to grow at a CAGR of 13.96% from 2024 to 2030.

3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave

Vistagen Therapeutics, Inc. (VTGN) Q3 2024 Earnings Call Transcript

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, today reported financial results for its fiscal year 2024 third quarter ended December 31, 2023 and provided a corporate update. "Momentum from clinical and corporate milestones achieved through the end of last quarter have significantly advanced our efforts to develop and co.

Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update

Nerdy

Rocket Lab USA

Entering 2024, a shift toward optimism emerges in the market, with eased monetary policies potentially opening doors for penny stocks to rebound. Savvy investors, drawn to overlooked opportunities, may find penny stocks appealing for their explosive long-term gains with even a modest investment.

3 Penny Stocks to Buy for the Next Bull Run: February 2024

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, today announced it will host a conference call and webcast on Tuesday, February 13, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2024 third quarter ended December 31, 2023 and provide a corporate update. Event: Vistagen Fiscal.

Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024

Biodesix

Powerbridge Technologies Co Ltd

Despite the recent economic deceleration, positive factors like a tight labor market and strong consumer spending support a resilient U.S. economy. Goldman Sachs predicts increased state and local government spending, and overall expectations suggest that, while there may be a short slowdown, the U.S. economy is anticipated to remain on a positive trajectory in 2024.

3 Penny Stocks to Turn $999 Into $1 Million: January 2024

Vistagen (VTGN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

How Vistagen (VTGN) Stock Stands Out in a Strong Industry

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #CNSdisorders--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that the European Patent Office (EPO) issued a Notice of Intention to Grant a patent related to the use of AV-101 for the treatment of neuropathic pain. AV-101 is the Company's investigational oral prodrug of 7-chloro-kyn.

Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain

Positive results achieved in phase 3 PALISADE-2 study for Fasedienol, a potential new treatment for social anxiety disorder. It is estimated that there are roughly 25 million people in the United States with this disorder. Itruvone is being advanced for the treatment of patients with major depressive disorder; A phase 2b study is expected to start in the 2nd half of 2024.

VistaGen: Positive Data Leads To Catalysts In 2024 And Beyond

Vistagen Therapeutics Inc (NASDAQ:VTGN) stock is enjoying quite the boost today, after Stifel initiated coverage with a "buy" rating and $12 price target.

Vistagen Therapeutics Stock Jumps on Fresh Coverage

Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q2 2024 Earnings Conference Call November 9, 2023 5:00 PM ET Company Participants Mark McPartland - Senior Vice President, Investor Relations Shawn Singh - Chief Executive Officer Cindy Anderson - Chief Financial Officer Josh Prince - Chief Operating Officer Conference Call Participants Andrew Tsai - Jefferies Tim Lugo - William Blair Operator Good day, everyone and welcome to today's Vistagen Fiscal Year 2024 Second Quarter Corporate Update Conference Call. [Operator Instructions] Please note this call is being recorded.

Vistagen Therapeutics, Inc. (VTGN) Q2 2024 Earnings Call Transcript

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today provided a corporate update and reported financial results for its fiscal year 2024 second quarter ended September 30, 2023. “Vistagen achieved multiple important milestones in recent months, significantly advancing our innovative.

Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that company management will present and host one-on-one meetings at the Stifel 2023 Healthcare Conference taking place November 14 – 15, 2023 at the Lotte New York Palace Hotel in New York City. Stifel 2023 Healthcare Co.

News for VistaGen Therapeutics Stock (VTGN)